Moderna wins big Merck investment | Chemical & Engineering News
Volume 94 Issue 27 | p. 15 | Concentrates
Issue Date: July 4, 2016

Moderna wins big Merck investment

Department: Business
Keywords: oncology, investment, rRNA, cancer, vaccines, anti-PD-1

Merck & Co. is paying Moderna Therapeutics $200 million in a deal to develop personalized cancer vaccines based on Moderna’s mRNA vaccine technology and Merck’s Keytruda anti-PD-1 cancer therapy. Moderna will use the money to lead the R&D effort and to help build a vaccine manufacturing facility in the Boston area. Moderna made news last year when it raised $450 million in the largest-ever biotech fund-raising. It struck an initial deal with Merck soon thereafter.

 
Chemical & Engineering News
ISSN 0009-2347
Copyright © American Chemical Society

Leave A Comment

*Required to comment